SUMMARY -High stroma proportion appears to be a very important prognostic factor in esophageal and breast cancer. Previous researches have shown that it might have a similar eff ect on colorectal cancer. Th e aim of this study was to determine whether tumor stroma proportion infl uenced patient survival. Th is retrospective study included 236 patients with colorectal cancer having undergone surgery in 2006 and 2007 at Osijek University Hospital Center. Location with the highest stroma proportion at the site of deepest tumor invasion was determined. Patients were divided into the groups with high stroma proportion (>50%) and low stroma proportion (≤50%). Stroma proportion showed a statistically signifi cant correlation with tumor stage. Kaplan-Meier survival curves yielded a statistically signifi cant diff erence in patient overall survival (Cox ph model p=0.016) and progressionfree survival (Cox ph model, p=0.0188) according to stroma proportion. Study results showed a statistically signifi cantly shorter overall survival and progression-free survival in patients with high stroma proportion.
Introduction
Colorectal cancer is a huge health issue. Unfortunately, the incidence and mortality of colorectal cancer have been growing in Croatia as opposed to developed countries 1, 2 . Postoperative patient treatment poses a special kind of problem 3 . Patients with disease stage I are not indicated any additional therapy after the surgery 4 . Patients with disease stage III are indicated additional chemotherapy after the surgery 5 . Patients with disease stage II present a special problem; about 25% of these patients have disease recurrence within 5 years 6 . Th e infl uence of additional chemotherapy on patients with disease stage II has been the basis for several clinical trials. Results of a meta-analysis of 5 trials have shown patients with disease stage III to benefi t most from additional chemotherapy [6] [7] [8] . However, new results of 12 controlled clinical studies from 1988 to 2010 have shown signifi cant benefi t of additional chemotherapy in patients with disease stage II 9 . On the other hand, the Quasar Collaborative Group study 6 has shown little benefi t of chemotherapy compared to no chemotherapy in patients with disease stage II. Th e benefi t was about 3.6%. Th is percentage is below the accepted level of 5% and therefore chemotherapy for the entire stage II group is not advised.
Numerous studies have shown which parameters mean worse prognosis for patients with colorectal cancer. Th ese parameters include evaluation of less than 12 lymph nodes 11 , lymphovascular or perineural invasion, poor tumor diff erentiation, younger age, close resection lines, and perforation during or after surgery 4, 12 . Based on these parameters, it is decided whether patients will receive chemotherapy.
In practice, we often encounter patients that have good prognostic factors but their metastatic disease develops very soon. Patients with a small primary tumor sometimes have a metastatic disease at the beginning.
A simple concept according to which tumor progression depends only on the intrinsic ability of tumor cells has been ever more widely rejected in the last couple of years. Th is points to the fact that tumor progression is the result of interaction between tumor and stroma cells, as well as the surrounding stroma cells 13, 14 . Th e researches known so far have confi rmed that tumor stroma infl uences tumor growth, angiogenesis and dissemination. It is believed that stroma induces tumorigenesis by various mechanisms such as remodeling of extracellular matrix, suppression of immune response and motility, as well as aggressiveness of cancer cells [15] [16] [17] . It has been evident that stroma has a prognostic value in esophageal cancer 18, 19 and breast cancer 20 , especially triple negative breast cancer 21, 22 . Using simple modifi ed methodology, we tried to determine the impact of stroma proportion on progression-free survival and overall survival. We also tried to determine the association of tumor stroma with previously known histopathologic features of the tumor. We tried to use simple, innovative methodology to quantifi y stroma proportion.
Patients and Methods
Our study included patients having undergone colorectal cancer surgery in 2006 and 2007 at Clinical Department of Surgery, and then treated or monitored at Clinical Department of Oncology, Osijek University Hospital Center. From analysis were excluded patients that had only colonoscopy and no surgery, and patients that died within a month after surgery (perioperative mortality). Patients that had received neoadjuvant oncologic therapy (neoadjuvant chemoradiotherapy for rectal cancer), patients with a history of malignant tumor and those with two synchronous colon cancers were not included in analysis. Considering patients having undergone surgery at Clinical Department of Surgery but not treated at Clinical Department of Oncology, Osijek University Hospital Center, only data that could be read from histopathologic fi ndings kept at Department of Pathology, Osijek University Hospital Center were included in analysis. Department of Pathology provided data on histopathologic features of the tumor (tumor size, tumor stage, number of lymph nodes removed, number of lymph nodes with tumor cells, tumor grade of diff erentiation, presence of lymphovascular or perineural invasion, tumor distance from resecting edge, and whether the patient underwent surgery for metastases). Medical history of patients provided by Clinical Department of Oncology included data on patient sex and age, date of surgery, type of surgery, metastases and their locations, and adjuvant treatment of patients. We also received information on the date of disease progression, date of the last examination, and date of death for the patients that died.
Our pathologist identifi ed the area of deepest tumor invasion with highest stroma proportion. Th en he took a photo of this area at 20X magnifi cation using Bx41 Olympus microscope with Olympus C-4040 digital camera. Using a computer program Adobe Photoshop CS2, we manually determined stroma area using green color (Fig. 1) . Th en we calculated the proportion of stroma based on the number of pixels (the number of green pixels/total image pixels (241968)). On most photos, tumor covered the whole photo, but on some photos it was not possible due to the size of the tumor (Fig. 2) . In this case, the number of yellow colored points was subtracted from the whole number of picture pixels. Th e areas of necrosis were yellow colored, while mucus that was part of the tumor was not yellow but remained colorless. Tumor stroma proportion was calculated afterwards. Th e cut-off point between high and low stroma proportion was set at 50%.
Statistics
Categorical data were presented as absolute and relative frequencies. Numerical data were presented as mean and standard deviation and, if necessary, with median and quartiles and other standard measures of descriptive statistics. Analysis of variance was used to determine relationship between stroma proportion and other histopathologic characteristics. Overall survival and progression-free survival were estimated by Kaplan-Meier survival curves. Diff erences in overall survival and progression-free survival were tested us- ing the Cox ph model, likelihood ratio test, and logrank test. Th e level of signifi cance was set at 0.05.
On statistical analysis, was used STATISTICA64 (version 11, StatSoft.Inc., Tulsa, OK, USA) statistical program and software package R, library "OIsurv" for survival analysis 23 .
Results
Th e analysis included 236 patients with all tumor stages, mean age 64.22 (standard deviation (SD) 11.46) years. Th ey all had undergone surgery at Cinical Department of Surgery, Osijek University Hospital Center, and 206 of them were then treated and followed up at Clinical Department of Oncology, Osijek University Hospital Center. Demographic characteristics of patients and histopathologic characteristics of tumors are shown in Table 1 .
We analyzed correlation between tumor stroma, pathologic characteristics of tumor and survival. Stroma proportion was determined in all study patients. Th e mean value of tumor stroma was 44.23% (SD 12.10%). Analysis of variance confi rmed a statistically signifi cant diff erence in stroma proportion due to tumor T stage (p=0.002) and N stage (p=0.038).
Relationship of the median overall survival and histopathologic characteristics of tumor is presented in Table 2 . Th ere was no statistically signifi cant diff erence in overall survival according to tumor localization, tumor diff erentiation, and perineural and lymphovascular invasion.
Relationship between progression-free survival and tumor characteristics is presented in Table 3 . Th ere was a statistically signifi cant diff erence in progression-free survival among all characteristics except for tumor differentiation.
Th e Cox proportional hazards methodology of modeling with a single predictor was used to analyze correlation between stroma proportion and patient survival. Th e likelihood ratio test revealed a statistically signifi cant role of tumor stroma proportion in the models of overall survival (p=0.016) and progressionfree survival (p=0.019). Th e Kaplan-Meier survival curves of overall survival and tumor stroma proportion are shown in Figure 3 , and Kaplan-Meier survival curves of progression-free survival and tumor stroma proportion in Figure 4 .
Discussion
Th e parameters associated with worse prognosis in patients with colorectal cancer include evaluation of less than 12 lymph nodes 10 , lymphovascular or perineural invasion, poor tumor diff erentiation, younger age, close resection lines, and perforation during or after surgery 3, 11 . Th ese parameters are not good enough to predict outcome in patients with colorectal cancer.
We need more and better parameters in clinical practice.
In recent research, some new parameters have emerged that may have a prognostic role in colorectal cancer, one of them being the amount of stroma, which was fi rst demonstrated as a prognostic factor in breast and esophageal cancer [17] [18] [19] [20] [21] [22] . Th e role of stroma proportion, or tumor cell proportion in the prognosis of colorectal cancer has been reported in four papers so far; they have demonstrated the proportion of stroma to be a signifi cant prognostic factor in colorectal cancer and the higher proportion of tumor stroma to be associated with better patient prognosis 24, 25, 28, 29 . In 2007, Mesker et al. showed the carcinoma-stroma ratio to be an independent factor for survival as compared with lymph node status and tumor stage 24 . In 2010, West et al. proved the smaller cancer cell proportion to be an independent prognostic factor for survival in colorectal cancer 25 . In 2012, the VICTOR trial was started 26, 27 . Th e authors planned to include 7000 pa- tients. Th e purpose of this study was to test whether the COX-2 inhibitor rofecoxib could reduce recurrence and improve survival when administered in the adjuvant setting of colorectal cancer stage II and III. Since cardiotoxicity of refecoxib had been established, the trial was stopped. Results of this huge trial including over 700 patients have confi rmed previous results that stroma is an independent prognostic factor in colorectal cancer stage II and III 28 , which was confi rmed in the study conducted by Park et al. in 2014 29 . Our trial confi rmed diff erence in overall survival and progression-free survival. Th is diff erence was statistically signifi cant, which is consistent with previous studies. Previous trials have shown strong heterogeneity in tumor cells within the tumor. Th e stroma proportion is not the same throughout the tumor. In breast cancer, some studies have shown that tumors with a high proportion of tumor cells at the periphery of the tumor have better prognosis 30 , while others report opposite fi ndings when looking at the entire tumor 31 . In previous trials, researchers used subjective methodology where two independent pathologists tried to estimate stroma proportion 27, 28 , while Mesker et al. used a software that is not available in every hospital 24 . In our trial, we tried to quantify stroma proportion using a simple, widely accessible methodology. Using this methodology, it is simple to determine stroma proportion. According to previous trials 24, 25, 28, 29 and the fact that it is impossible to determine stroma proportion in the whole tumor, we believe that the area with the largest stroma proportion at the site with deepest tumor penetration is adequate to analyze and set the stroma proportion as a prognostic factor for colorectal cancer.
In conclusion, our study showed the importance of tumor stroma proportion in determining outcome in patients with colorectal cancer. As it is simple to determine, it could be included as a prognostic parameter in the routine histopathologic reports.
